Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

First Vaccine For Chlamydia Developed By McMaster Researchers

XTALKS VITALS NEWS

Vaccine

The widely protective vaccine is the first of its kind to treat the often-asymptomatic infection.

Tweetables from this article:

Tweet: 113 million people worldwide are affected by chlamydia each year http://ctt.ec/2e14h+113 million people worldwide are affected by chlamydia each year.

Tweet: Chlamydial antigen called BD584, could have protective effects against the most common species of the bacterium http://ctt.ec/2J3BO+Chlamydial antigen called BD584, could have protective effects against the most common species of the bacterium.

Share this!

July 22, 2016 | by Sarah Massey, M.Sc.

A vaccine designed to prevent the common sexually-transmitted infection (STI), chlamydia, has been developed by researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University. The widely protective vaccine is the first of its kind to treat the often-asymptomatic infection.

It’s estimated that 113 million people worldwide are affected by chlamydia each year, and are at risk of losing fertility as a result of the infection. The results of the McMaster study – published in the journal, Vaccine – found that a chlamydial antigen called BD584, could have protective effects against the most common species of the parasitic bacterium, known as Chlamydia trachomatis.

Chlamydia often goes untreated due to its asymptomatic tendencies, potentially leading to pelvic inflammatory disease, upper genital tract infections and infertility. According to Dr. David Bulir, a former PhD study in medical sciences at McMaster, and lead author on the study, a vaccine for chlamydia could be extremely beneficial for global health.

“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said Bulir. “Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”



Bulir and his colleagues found that BD584 was able to limit chlamydial shedding – a symptom of C. trachomatis infection – by 95 percent. The potential vaccine candidate also decreased the symptoms associated with blocked fallopian tubes, known as hydrosalpinx, by 87.5 percent.

“Not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma,” said Steven Liang, a PhD student at McMaster and co-author on the study. Trachoma is an eye infection caused by the chlamydia bacteria and is the number one cause of preventable blindness around the world.

“The vaccine would be administered through the nose,” said Liang, in explaining how the immunization would be delivered. “This is easy and painless and does not require highly trained health professionals to administer, and that makes it an inexpensive solution for developing nations.”

Trachoma affects millions of people in mainly poorer regions around the world. The researchers say they plan to further develop different formulations of the vaccine, and test its effectiveness against other strains of chlamydia.


Keywords: Vaccine, Antigen, Infection


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Better Meal Planning for Diabetics Using a Predictive Blood Sugar App

April 21, 2017 - A new app could allow people with type 2 diabetes to make predictions about the impact of a meal on their blood sugar levels, before they even take a bite.

Featured In: Life Science News


Bacterial Biomarkers Could Make Diagnosing Colorectal Cancer Less Invasive

April 20, 2017 - Researchers at The University of Texas Health Science Center at Houston School of Public Health have identified specific strains of gut bacteria which have been associated with colorectal cancer.

Featured In: Life Science News


Weetabix Cereal Sold to Post in £1.4 Billion Deal

April 20, 2017 - The cereal was sold by Shanghai-based Bright Food, which acquired a controlling stake in the company in 2012.

Featured In: Food News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation

REGISTER FOR THESE WEBINARS

Electronic Informed Consent: 2017 Industry Survey Results


Critical CRO Oversight Metrics: How to Establish the Right Metrics and Monitor them in Real-Time


The Modernization of eCOA Technology for Clinical Trials


Developing a Biological Safety Evaluation


Copyright © 2016-2017 Honeycomb Worldwide Inc.